Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 07:10 ET | Source: Adagene Inc.

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development...
April 02, 2026 07:05 ET | Source: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune...
April 02, 2026 07:01 ET | Source: Research and Markets

Low-Grade Glioma Market Trends and Investment Opportunities Through 2030 & 2035: Regional Insights for Trametinib, Dabrafenib, Ivosidenib, and Mirdametinib

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Low-Grade Glioma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global low-grade glioma market is experiencing a...
April 02, 2026 07:01 ET | Source: Adagene Inc.

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide...
April 02, 2026 07:00 ET | Source: Sitryx Therapeutics

Sitryx nominates novel, oral GLS1 inhibitor for clinical development in moderate to severe asthma

Candidate has potential to be a first-in-class treatment offering biologic-like disease control from an oral small moleculeRegulatory submission preparation and entry into the clinic is expected in H1...
April 02, 2026 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
April 02, 2026 07:00 ET | Source: Neutrolis, Inc.

Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrationsNTR-1011 displayed a predictable...
April 02, 2026 07:00 ET | Source: Adagene Inc.

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement...
April 02, 2026 06:48 ET | Source: Research and Markets

Medulloblastoma Drugs Market Analysis and Growth Forecast 2026-2030 & 2035 by Drug Candidate, Product, Route of Administration, Distribution Channel, End-user and Region

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Medulloblastoma Drug Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, covering...
April 02, 2026 05:00 ET | Source: Roivant Sciences

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no...